Sandbox vidit2: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 13: | Line 13: | ||
{{familytree | | | D01 | | | | | | | | | | | | | |D01=Anticoagulation as needed based on the risk of stroke <br> Click [[Atrial fibrillation resident survival guide#Risk Factors for Stroke and Recommended Antithrombotic Therapy|here]] for the risk of stroke and anticoagulation therapy | {{familytree | | | D01 | | | | | | | | | | | | | |D01=Anticoagulation as needed based on the risk of stroke <br> Click [[Atrial fibrillation resident survival guide#Risk Factors for Stroke and Recommended Antithrombotic Therapy|here]] for the risk of stroke and anticoagulation therapy | ||
---- | ---- | ||
Recommended in all cases except lone AF (I A) <br> Measure INR weekly initially, then monthly when stable <br> Reassess need for anticoagulation at periodic intervals }} | Recommended in all cases except lone AF (I A) <br> Measure INR weekly initially, then monthly when stable (I A) <br> Reassess need for anticoagulation at periodic intervals (IIa C) }} | ||
{{familytree | | | | | | | | | | | | | | | | | | | }} | {{familytree | | | | | | | | | | | | | | | | | | | }} | ||
{{familytree | | | | | | | | | | | | | | | | | | | }} | {{familytree | | | | | | | | | | | | | | | | | | | }} | ||
| Line 21: | Line 21: | ||
{{familytree/end}} | {{familytree/end}} | ||
* Dabigatran may be used as an alternative to warfarin in those wdo don't have: | * Dabigatran may be used as an alternative to warfarin in those wdo don't have: (I B) | ||
:* Prosthetic heart valve | :* Prosthetic heart valve | ||
:* Hemodynamically significant valve disease | :* Hemodynamically significant valve disease | ||
:* Severe renal failure (creatinine clearance <15 mL/min) or | :* Severe renal failure (creatinine clearance <15 mL/min) or | ||
:* Advanced liver disease (impaired baseline clotting function). | :* Advanced liver disease (impaired baseline clotting function). | ||
* If patient on anticoagulants with AF sustains stroke or systemic embolism, target INR may be raised to 3.0 - 3.5 (IIb C). | |||
* Anticoagulation therapy can be interrupted for upto 1 week, if patients needs a procedure that carries a risk of bleeding. For periods > 1 week unfractionated or low molecular weight heparin may be given IV. | |||
Revision as of 17:01, 4 March 2014
| Newly discovered AF | |||||||||||||||||||||||||||||||||||||||||
| {{{-.}}} | |||||||||||||||||||||||||||||||||||||||||
| Paroxysmal | Persistent | ||||||||||||||||||||||||||||||||||||||||
| Look for the presence of one of these severe symptoms Hypotension Heart failure Angina pectoris Severe symptoms absent: Severe symptoms present: Attempt direct-current cardioversion | |||||||||||||||||||||||||||||||||||||||||
| Anticoagulation as needed based on the risk of stroke Click here for the risk of stroke and anticoagulation therapy Recommended in all cases except lone AF (I A) Measure INR weekly initially, then monthly when stable (I A) Reassess need for anticoagulation at periodic intervals (IIa C) | |||||||||||||||||||||||||||||||||||||||||
- Dabigatran may be used as an alternative to warfarin in those wdo don't have: (I B)
- Prosthetic heart valve
- Hemodynamically significant valve disease
- Severe renal failure (creatinine clearance <15 mL/min) or
- Advanced liver disease (impaired baseline clotting function).
- If patient on anticoagulants with AF sustains stroke or systemic embolism, target INR may be raised to 3.0 - 3.5 (IIb C).
- Anticoagulation therapy can be interrupted for upto 1 week, if patients needs a procedure that carries a risk of bleeding. For periods > 1 week unfractionated or low molecular weight heparin may be given IV.